Bexson Biomedical, a research stage company developing a proprietary ketamine-based subcutaneous treatment platform for pain management and mental health disorders, announced the addition of Bill Carson, MD as an advisor to the company.
In his position, Dr. Carson will provide perspective to Bexson's R&D program and guidance for its novel ketamine delivery platform.
Dr. Carson is an internationally recognized pharmaceutical and biotechnology leader, and has guided the global approval of several drugs and digital medicines. He is currently the Chairman of the Board, and the former President & CEO of Otsuka Pharmaceutical Development & Commercialization.
In a press release, Bexson Biomedical CEO Gregg Peterson said, “Dr. Carson's many FDA approvals and commercial success while leading Otsuka illustrate his ability to optimize technology in our highly regulated industry."
Dr. Carson stated, "I am encouraged by Bexson's R&D programs and hopeful that the company's technologic innovations will provide better treatment options for opioid-dependent patients."